Methylmethaqualone

Methylmethaqualone is a quinazolinone class GABAergic and is an analogue of methaqualone that was first made in 1965 and marketed mainly in France and some other European countries. It has sedative, hypnotic, and anxiolytic effects caused by its agonist activity at the β subtype of the GABA receptor, and was used for the treatment of insomnia.

Pharmacology

Methylmethaqualone differs from methaqualone by 3-methylation on the quinazoline. This makes it about twice as potent, and it was hoped it would be less addictive. However, it was still capable of causing dependence and serious side effects, and was therefore considered to be a controlled substance in many countries.

History

Methylmethaqualone was developed in the mid-1960s as a safer alternative to barbiturates to treat anxiety and insomnia. However, it was still capable of causing dependence and serious side effects. It was scheduled as a controlled substance in many countries due to these issues.

Side Effects

The side effects of Methylmethaqualone include dizziness, nausea, vomiting, and sweating. In severe cases, it can cause coma or death.

Legal Status

Methylmethaqualone is a controlled substance in many countries due to its potential for abuse and addiction. It is a Schedule I controlled substance in the United States.

See Also

• Methaqualone
• Quinazolinone
• GABAergic

Methylmethaqualone Resources
Latest articles Most recent articles Ongoing trials	Wikipedia